Advice

in the absence of a submission from the holder of the marketing authorisation:

tenofovir alafenamide (Vemlidy®) is not recommended for use within NHS Scotland.

Indication under review: Treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg).

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Download detailed advice58KB (PDF)

Download

Medicine details

Medicine name:
tenofovir alafenamide (Vemlidy)
SMC ID:
1238/17
Indication:
Treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg).
Pharmaceutical company
Gilead Sciences Ltd
BNF chapter
Infections
Submission type
Non submission
Status
Not recommended
Date advice published:
10 April 2017